Literature DB >> 16731441

Changes in bone mineral density following treatment of osteomalacia.

Rajiv Bhambri1, Vaishali Naik, Nidhi Malhotra, Shilpa Taneja, Saurabh Rastogi, Uma Ravishanker, Ambrish Mithal.   

Abstract

Osteomalacia is characterized by defective mineralization and low bone mineral density (BMD). Clinical and biochemical improvements typically occur within a few weeks of starting treatment, though the bone mineral deficits may take longer to correct. We report a case series of 26 patients with frank osteomalacia (pseudo fractures on X-rays, elevated serum total alkaline phosphatase and parathyroid hormone, normal/low serum calcium and phosphorus, and low serum 25-hydroxy vitamin D) who were followed-up for changes in BMD during treatment using dual- energy X-ray absorptiometry (DXA). There were 23 patients with nutritional vitamin D deficiency, 2 with malabsorption syndrome, and 1 with renal tubular acidosis. All patients were treated with vitamin D and calcium; the 3 patients with associated disorders were treated accordingly. At baseline, there was low BMD at all sites tested. The rate of increase in vertebral and hip BMD was rapid in the initial few months, which subsequently slowed down. In contrast to the large increases in BMD at the femoral neck and lumbar spine, the radial BMD did not recover. At the time when most patients had marked clinical and biochemical improvement (2.8+/-1.4 mo), the vertebral and hip BMD, although improved from baseline, had not completely recovered. Bone loss at the forearm (cortical site) appears to be largely irreversible. Although the clinical correlates of these changes are presently unclear, BMD measurements are useful in assessing the initial severity of bone loss as well as the response to therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731441     DOI: 10.1016/j.jocd.2005.11.001

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  24 in total

Review 1.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

2.  Recognizing the musculoskeletal manifestations of vitamin D deficiency.

Authors:  Andrea N Jones; Karen E Hansen
Journal:  J Musculoskelet Med       Date:  2009-10

3.  Osteomalacia in subtropical Auckland.

Authors:  Ravi K Narang; Ian Reid
Journal:  BMJ Case Rep       Date:  2019-07-08

4.  A case report of osteomalacia unmasking primary biliary cirrhosis.

Authors:  M Pawlowska; J E Kapeluto; D L Kendler
Journal:  Osteoporos Int       Date:  2015-03-24       Impact factor: 4.507

Review 5.  The role of vitamin D in maintaining bone health in older people.

Authors:  Thomas R Hill; Terry J Aspray
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-02-14       Impact factor: 5.346

6.  Osteomalacia revisited : a report on 28 cases.

Authors:  Laia Gifre; Pilar Peris; Ana Monegal; Maria Jesús Martinez de Osaba; Luisa Alvarez; Núria Guañabens
Journal:  Clin Rheumatol       Date:  2010-10-15       Impact factor: 2.980

Review 7.  Bone densitometry in patients with osteomalacia: is it valuable?

Authors:  Massoud Saghafi; Azita Azarian; Kamila Hashemzadeh; Maryam Sahebari; Zahra Rezaieyazdi
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

8.  High bone turnover persisting after vitamin D repletion: beware of calcium deficiency.

Authors:  M-H Lafage-Proust; L Lieben; G Carmeliet; C Soler; C Cusset; L Vico; T Thomas
Journal:  Osteoporos Int       Date:  2013-01-31       Impact factor: 4.507

Review 9.  Optimal vitamin D status for the prevention and treatment of osteoporosis.

Authors:  Michael F Holick
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 10.  Global vitamin D status and determinants of hypovitaminosis D.

Authors:  A Mithal; D A Wahl; J-P Bonjour; P Burckhardt; B Dawson-Hughes; J A Eisman; G El-Hajj Fuleihan; R G Josse; P Lips; J Morales-Torres
Journal:  Osteoporos Int       Date:  2009-06-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.